0 results

Patient Corner

Anatomical Illustrations

More

Latest drug updates

  • 28 Apr 2017 - Drug Updates

Valproate (Epilim▼, Depakote▼): High risk of neurodevelopmental disability and birth defects

Valproate should not be prescribed to women and girls of childbearing potential unless other treatments are ineffective or not tolerated.

Read more
  • 28 Apr 2017 - Drug Updates

Multiple sclerosis: Rebound syndrome after stopping fingolimod (Gilenya▼) or switching therapy

HCPs advised to report adverse effects associated with fingolimod (Gilenya▼) or other treatments for multiple sclerosis.

Read more
  • 19 Jul 2016 - Drug Updates

Rare reports of calciphylaxis in patients taking warfarin

Warfarin linked to cases of calciphylaxis, a very rare but serious condition

Read more
  • 19 Jul 2016 - Drug Updates

Suspected fatal drug interaction between citalopram and cocaine

Prescribers should consider possible illicit drug use when prescribing medicines with potential for interactions

Read more
  • 19 Apr 2016 - Drug Updates

Drug safety alert: Minimizing cardiac side effects associated with concomitant use of apomorphine and domperidone

Patients receiving apomorphine and domperidone require cardiac risk assessment and ECG monitoring to reduce the risk of serious arrhythmia related to QT-prolongation

Read more
  • 19 Apr 2016 - Drug Updates

Drug safety alert: Risks of PML, basal-cell carcinoma, and opportunistic infections associated with Fingolimod (Gilenya▼)

Fingolimod can increase the risk of progressive multifocal leukoencephalopathy and opportunistic infections owing to its immunomodulatory effects.

Read more
  • 19 Apr 2016 - Drug Updates

Drug safety update: Risk of progressive multifocal leukoencephalopathy with dimethyl fumarate (Tecfidera)

Reports of progressive multifocal leukoencephalopathy in patients receiving dimethyl fumarate for multiple sclerosis, who all had prolonged lymphopenia

Read more
  • 4 Oct 2016 - Drug Updates

Ongentys (opicapone) approved for treatment of Parkinson's disease

Ongentys has been licensed in the UK for adjunctive treatment of Parkinson's disease

Read more